QRHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
QRHC is not a good buy right now. The technical setup is only mildly constructive, but there are no proprietary buy signals, no near-term catalysts, weakening YoY revenue/EPS trends in 2025/Q3, and the pattern-based outlook skews slightly negative over the next month. For an impatient buyer who wants an immediate edge, this does not offer a compelling entry today—avoid/stand aside.
Trend/structure: Mild bullish bias from moving averages (SMA_5 > SMA_20 > SMA_200), suggesting an improving longer-term structure. Momentum: MACD histogram is positive (0.0128) but contracting, implying upside momentum is fading rather than accelerating. RSI(6)=51.24 is neutral—no strong overbought/oversold edge. Levels: Current price 2.11 is slightly below the pivot (2.148), so it’s not reclaiming the key decision level yet. Near support S1=1.944 (then S2=1.819); resistance R1=2.351 and R2=2.477. Probabilistic trend read: Similar-pattern analysis implies modest upside next day/week (+1.08% / +0.56%) but a negative bias over the next month (-1.5%), aligning with the fading MACD.
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Technicals: Bullish moving-average stack supports a constructive longer-term base. Options: Strong call skew (very low put-call ratios) suggests traders are positioned for upside. No notable hedge fund or insider selling pressure reported (both neutral).
No news/catalysts in the last week to drive an immediate rerating. Momentum is weakening (MACD histogram contracting) and price is below pivot (2.148), increasing risk of drifting toward support (1.944). Pattern-based forward view is slightly negative over 1 month (-1.5%). Options are extremely high IV vs realized, which often means paying up for uncertainty. Politician/congress activity: No recent congress trading data available (no supportive signal).
Latest quarter: 2025/Q3. Revenue fell to $63.34M (-12.95% YoY). Net income declined to -$1.349M (worse by -60.15% YoY), and EPS fell to -0.06 (-62.50% YoY). The bright spot is gross margin improving to 16.04% (+25.02% YoY), but the overall growth trend is negative (top-line and earnings deterioration), which reduces the odds of a near-term upside breakout without a catalyst.
No analyst rating or price target change data was provided, so there’s no observable recent Wall Street upgrade/downgrade trend to support a decisive buy case. Pros (typical bull view): margin improvement and potential operating leverage if revenue stabilizes. Cons (typical bear view): declining revenue and worsening losses/EPS, limited visible catalysts, and high uncertainty implied by options.
